Department of Pediatrics, West China Second University Hospital, Sichuan University, China.
CNS Neurol Disord Drug Targets. 2011 Mar;10(2):235-8. doi: 10.2174/187152711794480456.
Hypoxia/ischemia brain damage (HIBD) is one of the most common central nervous system insults in newborns. Brain repair following HIBD is closely associated with cellular processes such as cell survival, angiogenesis, and neurogenesis. In recent years, many studies have suggested that ginsenoside Rg1, one of the major active ingredients of ginseng, may increase neural viability, promote angiogenesis, and induce neurogenesis. However, there are few reports on roles of Rg1 in HIBD repair, and the mechanisms involved are unclear. Recently, a Chinese drug consisting of Rg1 has been shown to be a potential regulator of hypoxia-inducible factor-1α expression in HIBD. Since it has been shown that HIF-1α is a key transcription factor involved in the neuroprotective response to HIBD, it is possible that Rg1 could facilitate the process of brain repair, possibly modulating cell survival, angiogenesis, and neurogenesis after HIBD by targeting HIF-1α.
缺氧缺血性脑损伤(HIBD)是新生儿中最常见的中枢神经系统损伤之一。HIBD 后的脑修复与细胞存活、血管生成和神经发生等细胞过程密切相关。近年来,许多研究表明,人参的主要活性成分之一人参皂苷 Rg1 可能增加神经活力、促进血管生成和诱导神经发生。然而,关于 Rg1 在 HIBD 修复中的作用的报道很少,涉及的机制也不清楚。最近,一种由 Rg1 组成的中药已被证明是 HIBD 中缺氧诱导因子-1α表达的潜在调节剂。由于已经表明 HIF-1α 是参与 HIBD 神经保护反应的关键转录因子,因此 Rg1 可能通过靶向 HIF-1α 促进脑修复过程,可能通过调节 HIBD 后细胞存活、血管生成和神经发生。